| Name | Title | Contact Details |
|---|
Statistical Center for HIV/AIDS Research and Prevention is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ONI is a pioneer of next generation super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world`s first benchtop sized super-resolution microscope, delivers a step change in usability and precision. The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal. The company`s achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard. ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. We have a vision for making high tech science available to anyone, anywhere, from the research bench to your doctor`s office.
GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics` pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics` lead product candidate, GS010, is in Phase III trials in Leber`s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics` product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.
GeneGo bioinformatics software, Inc. is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.